세계의 만성 B형 간염 시장 보고서(2025년)

Chronic hepatitis B results from a prolonged infection with the hepatitis B virus (HBV), lasting more than six months. It can potentially cause severe liver damage, liver failure, or liver cancer. While often asymptomatic for years, it can be identified through blood tests and requires ongoing management with antiviral medications and regular monitoring.

In treating chronic hepatitis B, medications primarily consist of antivirals and immunomodulators. Antivirals are specifically designed to hinder the replication and growth of viruses. They play a crucial role in managing chronic hepatitis B by reducing the viral load in the liver and slowing the progression of liver damage.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The chronic hepatitis B market research report is one of a series of new reports from the business research company that provides chronic hepatitis B market statistics, including chronic hepatitis B industry global market size, regional shares, competitors with an chronic hepatitis B market share, detailed chronic hepatitis B market segments, market trends and opportunities, and any further data you may need to thrive in the chronic hepatitis B industry. This chronic hepatitis B market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The chronic hepatitis b market size has grown steadily in recent years. It will grow from $3.77 billion in 2024 to $3.93 billion in 2025 at a compound annual growth rate (CAGR) of 4.2%. The growth in the historic period can be attributed to advances in antiviral therapy, growing government and NGO initiatives, improved diagnostic techniques, the rising prevalence of HIV, and increasing awareness.

The chronic hepatitis b market size is expected to see steady growth in the next few years. It will grow to $4.59 billion in 2029 at a compound annual growth rate (CAGR) of 4.0%. The growth in the forecast period can be attributed to expansion in emerging markets, growing government policies and funding, improved diagnostics and screening, rising healthcare expenditure, increasing strategic collaborations and partnerships, a growing aging population, and growing public awareness campaigns. Major trends in the forecast period include a shift towards curative therapies, expansion in emerging markets, enhanced diagnostics and screening, partnerships and collaborations, and a focus on patient-centric care.

The forecast of 4.0% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. hepatology care by inflating prices of tenofovir formulations and HBV viral load test kits developed in India and Germany, resulting in delayed viral suppression and higher liver disease management costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The high prevalence of chronic hepatitis B infection is expected to drive the growth of the chronic hepatitis B virus market in the future. Hepatitis B is a liver infection caused by the hepatitis B virus (HBV) and can be prevented through vaccination. The rise in hepatitis B infection rates is largely due to low vaccination coverage, especially in low- and middle-income countries, leading to higher transmission rates as significant portions of the population remain unprotected. Increasing rates of hepatitis B infection are likely to boost demand for diagnostic tests and treatment options. For instance, according to a report published in June 2024 by the Centers for Disease Control and Prevention (CDC), a US-based government agency, increasing global hepatitis B vaccination coverage to 90% and treatment access to 80% could prevent 26 million new infections and 9 million deaths due to hepatitis B from 2022 to 2050. In 2022 alone, there were 1.2 million new cases of HBV infection. Consequently, the high prevalence of hepatitis B infection is expected to drive growth in the chronic hepatitis B virus market.

Leading companies in the chronic hepatitis B market are prioritizing technological advancements, such as novel antiviral therapies. These innovative therapies target viral infections, including resistant strains, by inhibiting viral replication and incorporating advanced delivery systems, with ongoing clinical trials assessing their safety and efficacy, such as bepirovirsen for chronic hepatitis B. For example, in February 2024, GSK plc, a UK-based multinational pharmaceutical and biotechnology company specializing in the research, development, manufacturing, and marketing of healthcare products, received the U.S. Food and Drug Administration (FDA) Fast Track designation for bepirovirsen, an investigational antisense oligonucleotide (ASO) for chronic hepatitis B (CHB). Bepirovirsen is designed to degrade the RNA of the hepatitis B virus (HBV), potentially enabling the immune system to regain control over the infection. The drug has shown promising results in Phase IIb trials, specifically the B-Clear and B-Sure studies, where it demonstrated efficacy in reducing hepatitis B surface antigen (HBsAg) levels and achieving sustained viral suppression.

In November 2023, GSK plc, a pharmaceutical company headquartered in the UK, acquired exclusive rights to a hepatitis B therapy from Janssen Pharmaceuticals for $1 billion. The acquisition includes the rights to JNJ-3989 (also known as ARO-HBV), an antisense oligonucleotide drug. Through this acquisition, GSK aims to enrich its portfolio and reinforce its position in the treatment of chronic hepatitis B by introducing a promising new therapy. Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson based in Belgium, specializes in developing treatments for a range of serious and complex diseases, including infectious diseases such as chronic hepatitis B.

Major companies operating in the chronic hepatitis b market are Pfizer Inc., F Hoffmann-La Roche Ltd, Merck & Co Inc, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Dynavax Technologies Corporation, Gilead Sciences Inc, Viatris Inc., Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Apotex Corp, Cipla Ltd, Hikma Pharmaceuticals, Lupin Pharmaceuticals Inc, Vir Biotechnology Inc, VBI Vaccines Inc, Shenzhen Hepalink Pharmaceutical Co. Ltd., Accord Healthcare Inc, Par Pharmaceutical Inc, Arrowhead Pharmaceuticals Inc, ViiV Healthcare, Arbutus Biopharma Corporation, Ascentage Pharma, ENYO Pharma, Zydus Pharmaceuticals Inc, Nucorion Pharmaceuticals

North America was the largest region in the chronic hepatitis B market in 2024. The regions covered in the chronic hepatitis b market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the chronic hepatitis b market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The chronic hepatitis B market consists of revenues earned by entities by providing services such as diagnostic testing, treatments, liver function monitoring, patient education, and support programs .The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic hepatitis B market also includes sales of medications, interferons, liver transplant medications, diagnostic kits, liver biopsy equipment, and HBV vaccines. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Chronic Hepatitis B Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on chronic hepatitis b market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for chronic hepatitis b ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The chronic hepatitis b market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Antivirals; Immune Modulators
• 2) By Gender: Male; Female
• 3) By Distribution Channel: Hospital Pharmacies; Drug Stores And Retail Pharmacies; Online Providers
• Subsegments:
• 1) By Antivirals: Nucleos(T)Ide Analogs (Tenofovir, Entecavir); Interferons (Pegylated Interferon)
• 2) By Immune Modulators: Immune Checkpoint Inhibitors; Therapeutic Vaccines (HBV Vaccines Under Development)
• Companies Mentioned: Pfizer Inc.; F Hoffmann-La Roche Ltd; Merck & Co Inc; Bristol-Myers Squibb Company; Novartis AG; GlaxoSmithKline plc; Dynavax Technologies Corporation; Gilead Sciences Inc; Viatris Inc.; Teva Pharmaceutical Industries Limited; Sun Pharmaceutical Industries Ltd.; Aurobindo Pharma Limited; Dr. Reddy's Laboratories Ltd.; Apotex Corp; Cipla Ltd; Hikma Pharmaceuticals; Lupin Pharmaceuticals Inc; Vir Biotechnology Inc; VBI Vaccines Inc; Shenzhen Hepalink Pharmaceutical Co. Ltd.; Accord Healthcare Inc; Par Pharmaceutical Inc; Arrowhead Pharmaceuticals Inc; ViiV Healthcare; Arbutus Biopharma Corporation; Ascentage Pharma; ENYO Pharma; Zydus Pharmaceuticals Inc; Nucorion Pharmaceuticals
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Chronic Hepatitis B Market Characteristics

3. Chronic Hepatitis B Market Trends And Strategies

4. Chronic Hepatitis B Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Chronic Hepatitis B Growth Analysis And Strategic Analysis Framework

• 5.1. Global Chronic Hepatitis B PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Chronic Hepatitis B Market Growth Rate Analysis
• 5.4. Global Chronic Hepatitis B Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Chronic Hepatitis B Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Chronic Hepatitis B Total Addressable Market (TAM)

6. Chronic Hepatitis B Market Segmentation

• 6.1. Global Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antivirals
• Immune Modulators
• 6.2. Global Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Male
• Female
• 6.3. Global Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Drug Stores And Retail Pharmacies
• Online Providers
• 6.4. Global Chronic Hepatitis B Market, Sub-Segmentation Of Antivirals, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nucleos(T)Ide Analogs (Tenofovir, Entecavir)
• Interferons (Pegylated Interferon)
• 6.5. Global Chronic Hepatitis B Market, Sub-Segmentation Of Immune Modulators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immune Checkpoint Inhibitors
• Therapeutic Vaccines (HBV Vaccines Under Development)

7. Chronic Hepatitis B Market Regional And Country Analysis

• 7.1. Global Chronic Hepatitis B Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Chronic Hepatitis B Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Chronic Hepatitis B Market

• 8.1. Asia-Pacific Chronic Hepatitis B Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Chronic Hepatitis B Market

• 9.1. China Chronic Hepatitis B Market Overview
• 9.2. China Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Chronic Hepatitis B Market

• 10.1. India Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Chronic Hepatitis B Market

• 11.1. Japan Chronic Hepatitis B Market Overview
• 11.2. Japan Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Chronic Hepatitis B Market

• 12.1. Australia Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Chronic Hepatitis B Market

• 13.1. Indonesia Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Chronic Hepatitis B Market

• 14.1. South Korea Chronic Hepatitis B Market Overview
• 14.2. South Korea Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Chronic Hepatitis B Market

• 15.1. Western Europe Chronic Hepatitis B Market Overview
• 15.2. Western Europe Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Chronic Hepatitis B Market

• 16.1. UK Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Chronic Hepatitis B Market

• 17.1. Germany Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Chronic Hepatitis B Market

• 18.1. France Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Chronic Hepatitis B Market

• 19.1. Italy Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Chronic Hepatitis B Market

• 20.1. Spain Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Chronic Hepatitis B Market

• 21.1. Eastern Europe Chronic Hepatitis B Market Overview
• 21.2. Eastern Europe Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Chronic Hepatitis B Market

• 22.1. Russia Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Chronic Hepatitis B Market

• 23.1. North America Chronic Hepatitis B Market Overview
• 23.2. North America Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Chronic Hepatitis B Market

• 24.1. USA Chronic Hepatitis B Market Overview
• 24.2. USA Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Chronic Hepatitis B Market

• 25.1. Canada Chronic Hepatitis B Market Overview
• 25.2. Canada Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Chronic Hepatitis B Market

• 26.1. South America Chronic Hepatitis B Market Overview
• 26.2. South America Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Chronic Hepatitis B Market

• 27.1. Brazil Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Chronic Hepatitis B Market

• 28.1. Middle East Chronic Hepatitis B Market Overview
• 28.2. Middle East Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Chronic Hepatitis B Market

• 29.1. Africa Chronic Hepatitis B Market Overview
• 29.2. Africa Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Chronic Hepatitis B Market Competitive Landscape And Company Profiles

• 30.1. Chronic Hepatitis B Market Competitive Landscape
• 30.2. Chronic Hepatitis B Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co Inc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Chronic Hepatitis B Market Other Major And Innovative Companies

• 31.1. GlaxoSmithKline plc
• 31.2. Dynavax Technologies Corporation
• 31.3. Gilead Sciences Inc
• 31.4. Viatris Inc.
• 31.5. Teva Pharmaceutical Industries Limited
• 31.6. Sun Pharmaceutical Industries Ltd.
• 31.7. Aurobindo Pharma Limited
• 31.8. Dr. Reddy's Laboratories Ltd.
• 31.9. Apotex Corp
• 31.10. Cipla Ltd
• 31.11. Hikma Pharmaceuticals
• 31.12. Lupin Pharmaceuticals Inc
• 31.13. Vir Biotechnology Inc
• 31.14. VBI Vaccines Inc
• 31.15. Shenzhen Hepalink Pharmaceutical Co. Ltd.

32. Global Chronic Hepatitis B Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Chronic Hepatitis B Market

34. Recent Developments In The Chronic Hepatitis B Market

35. Chronic Hepatitis B Market High Potential Countries, Segments and Strategies

• 35.1 Chronic Hepatitis B Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Chronic Hepatitis B Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Chronic Hepatitis B Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer